摘要
目的:对比观察依达拉奉联合神经节苷脂治疗急性脑梗死临床效果及安全性,为临床用药作出指导。方法:选择我院自2010年1月至2012年1月收治的67例急性脑梗死患者为研究对象,随机分为两组。实验组给予依达拉奉联合单唾液酸四己糖神经节苷脂治疗,对照组仅予以单唾液酸四己糖神经节苷脂,对比观察两组患者治疗后NHISS评分情况、临床疗效情况。结果:两组患者治疗前NIHSS评分无统计学差异(P>0.05),两组患者治疗前后NIHSS评分均有统计学差异(P<0.05),两组患者NIHSS评分差值比较具有统计学意义(P<0.05)。实验组显效率为36.36%,对照组显效率为20.59%,两组比较具有显著差异(P<0.05),实验组有效率为69.70%,对照组有效率为40.09%,两组比较具有统计学差异(P<0.05)。结论:依达拉奉联合神经节苷脂和单独使用神经节苷脂治疗急性脑梗死临床效果均好,但是联合用药对患者NHISS评分影响更大,值得临床广泛推广。
Objective：To compare clinical effect and safety of edaravone joint ganglioside treatment of acute cerebral infarction ,for clinical guidance.Methods：Slected 67 patients with acute cerebral infarction patients admitted to our hospital from January 2010 to January 2012 as the research object, randomly divided them into two groups. Experimental group were given edaravone joint ganglioside treatment, the control group were given ganglioside , compared the NHISS score and the clinical efficacy of two groups after received treatment.Results：The NIHSS score of two groups of patients before treatment had no significant difference （P〉0.05）, NIHSS score in both of the two groups after treatment had statistically significant than the score before received treatment（P〈0.05）, the NIHSS score difference between two groups of patients had statistically significant （P〈0.05）. Experimental group Significant efficiency rate is 36.36%, while the control group was 20.59%,which were significant different （P〈0.05）, the effective rate of experimental group was 69.70%, while the control group was 40.09%, which were statistically different （P〈0.05）.Conclusion：Both of Edaravone joint ganglioside and ganglioside used alone for acute cerebral infarction have good clinical effects , but the the the United medication of patients has greater impact in NHISS score , which is worthy of clinical widely.
出处
《中国医药导刊》
2013年第9期1486-1487,1489,共3页
Chinese Journal of Medicinal Guide
